Gossamer Bio entered into a securities purchase agreement for a structured private placement with aggregate gross proceeds of up to $250 million. The initial closing, expected August 24, 2026, will generate approximately $25 million from pre-funded warrants priced at $0.1399 each. A second closing is committed upon FDA acceptance of the New Drug Application for seralutinib in pulmonary arterial hypertension, providing an additional $125 million. If the FDA approves seralutinib, investors may exercise FDA Approval Warrants to provide up to $100 million more. Proceeds will fund clinical development and operations into 2028. Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib for pulmonary arterial hypertension.
